Mar 28, 2023 / 04:30PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thank you very much everybody for continuing along this afternoon. It's my pleasure to host Eiry Roberts, Neurocrine Chief -- Chief Medical Officer; and Kyle Gano, Head of BD and Strategy at Neurocrine. So thank you both very much.
Questions and Answers:
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior AnalystI though we would just kind of center discussion to start on crinecerfont, the focal seizure readout later this year. And then maybe you can talk a little bit more about your broader strategy. But maybe to start with crinecerfont, I guess the main overarching question that I and other investors have is how do we take the initial biomarker data that's been has been generated, which looks very promising and try to extrapolate that or predict in broader confidence in a clinically meaningful level of steroid dose reduction. So
Trustpilot
